ジョージア州における慢性リンパ性白血病の臨床試験
ジョージア州内の拠点で、慢性リンパ性白血病に関する16件の研究が参加者を募集しています。
ジョージア州内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- 他4件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Emory University Winship Cancer Institute, Atlanta
- Northside Cancer Center, Atlanta
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06846671Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Atlanta, Newnan
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Central Georgia Cancer Care, Macon
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07516093A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
被験者募集中第1相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07020533Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/06更新 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- City of Hope Atlanta Cancer Center, Newnan
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT07218510CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
被験者募集中第2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/03/10更新 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- The Emory Clinic, Atlanta
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- The Emory Clinic, Atlanta
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Winship Cancer Institute of Emory University /ID# 230643, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/09更新 · NCT04895436Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Winship Cancer Institute at Emory University, Atlanta
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06043674ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。